<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01949935</url>
  </required_header>
  <id_info>
    <org_study_id>NBHC-MIR004</org_study_id>
    <nct_id>NCT01949935</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting</brief_title>
  <acronym>MIR-CABG</acronym>
  <official_title>MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Horizon Health Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Horizon Health Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that application of Mupirocin to the nose before and after coronary artery
      bypass grafting surgery will reduce the incidence of surgical site infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mupirocin applied to the nares is effective in eradicating nasal carriage of Staphylococcus
      species. Abundant evidence has documented that a majority of gram positive surgical site
      infections share bacterial phenotypes identical with nasal phage types. Conflicting
      literature exists regarding the efficacy of mupirocin in reducing the incidence of surgical
      site infections. A randomized prospective double-blind placebo-controlled trial is needed to
      help settle this question in the setting of coronary artery bypass grafting surgery where
      surgical site infections carry significant morbidity, cost, and mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical Site Infection</measure>
    <time_frame>&lt;30 days post operation</time_frame>
    <description>Surgical site infections (SSI) are classified as superficial, deep, or organ surgical site infections based on CDC definition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>&lt; or = 30 days post operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse durg effects</measure>
    <time_frame>&lt; or = 30 day post operation</time_frame>
    <description>Rashes, rhinorrhea, pruritis, bleeding from nares</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S. aureus carrier status</measure>
    <time_frame>&lt; or = 30 day post operation</time_frame>
    <description>Nasal carriage of Staphylococcus aureus assess pre-intervention and post-intervention.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of subtypes of surgical site infections.</measure>
    <time_frame>&lt; or = 30 days post operation.</time_frame>
    <description>Subtypes include deep sternal wound, mediastinitis, leg saphenous vein harvest site infections.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of pneumonia</measure>
    <time_frame>&lt; or = 30 days post operation.</time_frame>
    <description>As diagnosed by sputum, radiographic, and clinical means.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">974</enrollment>
  <condition>Surgical Site Infections</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo made from Glaxal base Applied once 1 day preoperatively and bid for 3 days postoperatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mupirocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mupirocin ointment applied to nares once 1 day preoperatively and bid for 3 days postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mupirocin</intervention_name>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Mupirocin</arm_group_label>
    <other_name>Bactroban</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt;18 years old undergoing Coronary Artery Bypass Grafting Surgery (CABG) with or
             without concomitant cardiac valve surgery or other cardiac surgery,

          -  Median sternotomy wound

          -  Capable of informed consent

        Exclusion Criteria:

          -  Allergy to mupirocin or components

          -  Pregnant or lactating females

          -  Emergency surgery

          -  Pre-existing ongoing infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig D Brown, BSc (Med), MD, FRCSC, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Brunswick Heart Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Brunswick Heart Centre, Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Horizon Health Network</investigator_affiliation>
    <investigator_full_name>Dr Craig Brown</investigator_full_name>
    <investigator_title>Director of Clinical Trials, New Brunswick Heart Centre</investigator_title>
  </responsible_party>
  <keyword>Mupirocin</keyword>
  <keyword>Surgical Site Infections</keyword>
  <keyword>Coronary Artery Bypass Grafting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mupirocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

